Gastrointestinal Therapeutics Market Size, Share & Trends Analysis Report By Product (OTC Gastrointestinal Therapeutics, Prescription-Based Gastrointestinal Therapeutics), By Application (Irritable Bowel Syndrome, Peptic Ulcer Disease (PUD), Gastroenteritis, GI Bleeding, Others), By End-Users (Hospitals, Clinics, Others), By Dosage Form (Injections, Oral) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Gastrointestinal Therapeutics Market Size

The global gastrointestinal therapeutics market size was valued at USD 40.8 billion in 2025 and is projected to grow from USD 42.47 billion in 2026 to USD 58.58 billion by 2034, registering a CAGR of 4.1% during the forecast period from 2026 to 2034. North America dominated the gastrointestinal therapeutics market with a market share of 38.4% in 2025.

A medical condition known as gastrointestinal (GI) syndrome disrupts the normal functioning of the organs that are located in the digestive tract. Indigestion, heartburn, constipation, and bloating are commonly associated with this condition, affecting the stomach, pancreas, small and large intestines, gall bladder, and liver. Antacids, laxatives, antidiarrheal agents, antiemetics, antiulcer agents, endoscopic and radiological procedures, and hematological tests are just some over-the-counter (OTC) drugs like prescription medications that are included in the category of gastrointestinal (GI) therapeutics that are frequently used. These therapies help diagnose the condition and absorb nutrients from meals to enhance digestion, regulate water flow throughout the gastrointestinal tract, and reduce the amount of gastric acid produced.

One of the primary forces behind expanding the market is the rising incidence of gastrointestinal conditions, including inflammatory bowel disease (IBD) and ulcerative colitis. It is one of the crucial elements driving the growth of the market. Patients all over the world are at an elevated risk of having a relapse of their condition because of shifting lifestyle patterns and improper food habits. This industry is also benefiting from an ageing population, which is more prone to illnesses like diabetes and heart disease. Other growth-inducing elements include technological breakthroughs, such as developing novel biosimilars and cellular therapies for treating the illness. These types of treatments are currently being researched and developed.

Segmental Insights

The global gastrointestinal therapeutics market is segmented into five parts based on product, application, end-users, dosage form, and region.

Further, the market is divided into OTC Gastrointestinal Therapeutics and Prescription Based Gastrointestinal Therapeutics based on product.

Request Customizationto receive a tailored report.

The market is classified into Irritable Bowel Syndrome, Peptic Ulcer Disease (PUD), Gastroenteritis, GI Bleeding, and others based on application.

The market is divided into Hospitals, Clinics, and others based on end-users.

Speak to an Analystto discuss market opportunities.

Regional Insights

It is anticipated that the gastrointestinal therapeutics market growth will receive a boost from expanding the market for gastrointestinal therapeutics in North America. It is because of rising healthcare spending and initiatives taken by the government to increase awareness of and access to more effective gastrointestinal therapy options in the region.

Asia Pacific Gastrointestinal Therapeutics Market Trends

The market for gastrointestinal treatments in the Asia Pacific, excluding China, is anticipated to develop at the highest CAGR due to an increasing patient pool due to an unclean and sedentary lifestyle and inadequate sanitation facilities in this area.

Unlock Regional Insightsto access country-level data, & regional trends.

List of Key and Emerging Players in Gastrointestinal Therapeutics Market